Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimer's disease
about
Mild cognitive impairment: pathology and mechanisms.Analyzing the genes related to Alzheimer's disease via a network and pathway-based approachLongitudinal measures of cholinergic forebrain atrophy in the transition from healthy aging to Alzheimer's disease.Basal forebrain atrophy and cortical amyloid deposition in nondemented elderly subjectsCholinergic basal forebrain atrophy predicts amyloid burden in Alzheimer's disease.National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's diseaseArizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program.Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literatureDistribution of secretagogin-containing neurons in the basal forebrain of mice, with special reference to the cholinergic corticopetal system.Striatal amyloid plaque density predicts Braak neurofibrillary stage and clinicopathological Alzheimer's disease: implications for amyloid imaging.Nonvascular retinal imaging markers of preclinical Alzheimer's disease.Impaired NGF/TrkA Signaling Causes Early AD-Linked Presynaptic Dysfunction in Cholinergic Primary NeuronsEarly and Late Pathomechanisms in Alzheimer's Disease: From Zinc to Amyloid-β NeurotoxicityCholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer's disease.M1 muscarinic acetylcholine receptor in Alzheimer's diseaseReduced cholinergic olfactory centrifugal inputs in patients with neurodegenerative disorders and MPTP-treated monkeys.Higher levels of different muscarinic receptors in the cortex and hippocampus from subjects with Alzheimer's disease.Rapid β-amyloid deposition and cognitive impairment after cholinergic denervation in APP/PS1 mice.Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer's disease.The potent M1 receptor allosteric agonist GSK1034702 improves episodic memory in humans in the nicotine abstinence model of cognitive dysfunction.Regional covariance of muscarinic acetylcholine receptors in Alzheimer's disease using (R, R) [(123)I]-QNB SPECT.Acute Effects of Muscarinic M1 Receptor Modulation on AβPP Metabolism and Amyloid-β Levels in vivo: A Microdialysis Study.Cholinergic Basal Forebrain Lesion Decreases Neurotrophin Signaling without Affecting Tau Hyperphosphorylation in Genetically Susceptible Mice.Muscarinic M1 Receptor Coupling to G-protein is Intact in Parkinson's Disease Dementia.Association of Neuropathological Markers in the Parietal Cortex With Antemortem Cognitive Function in Persons With Mild Cognitive Impairment and Alzheimer Disease.Detection of Striatal Amyloid Plaques with [18F]flutemetamol: Validation with Postmortem Histopathology.Amyloid-β interrupts canonical Sonic hedgehog signaling by distorting primary cilia structureThe cholinergic system in the pathophysiology and treatment of Alzheimer's disease
P2860
Q24631255-C08AE0BF-6C8C-4329-8229-29B8F54F6B78Q33608642-0785B536-E440-49BA-AF7C-C114D6F989C3Q33759008-971964FB-BFFC-4CE2-994A-845C8481298FQ33882427-13AD1646-6104-41FF-9DFF-E430FB21608CQ33998690-53DC66FF-9C7F-4153-BA51-E3ECB8FFDAB6Q34635272-C13CF1F2-14CE-4AEF-ABB2-2191C66517AEQ36121377-B43EDDCA-9054-4073-9A9C-E3A5CB095764Q36575903-7030C610-E837-42C4-AC3D-FCE3309CFB0FQ36771923-F2282C6D-71B8-4BD0-9526-E7538309D982Q37141423-5D258B36-1E9D-48DD-A4BD-8AE131865B5FQ37363628-EA53036A-321B-4A18-9B93-6E5509758C83Q37699616-561B500D-55D7-4821-A490-0D105A197126Q37710159-945F5826-1516-4EFC-88CA-502E86286291Q37961834-F07F8AAB-4870-4E0D-A6E5-7D2D0C8143F2Q38192962-258F5B18-A803-4D3C-9FD1-885B900DC339Q38314696-82E15F42-44D8-4B06-9295-8793996AF594Q39336083-52879648-0BB3-4C81-BC75-243B7F792B92Q39460000-DFEF2930-212D-4C5B-BD7D-E8FE48BEA5EDQ41718243-833F65EB-6EC7-4AC4-AF4A-AC6CF35AB931Q44842565-D2082BD3-9AC3-45C6-8FEF-10CE8F05CDB1Q48103246-7F0C31C0-4DE6-4182-B7BB-BE510FE4B498Q48226341-041887CE-56AA-4EE5-B0ED-429CFA0AABB0Q48467687-C69BD829-F949-4C0C-8FE8-93A16339177EQ48468765-22B4A490-AC05-43D6-AA84-1EBC1D1089C9Q51154144-498487B2-9629-4DC2-A294-C785A68D8EA8Q52142982-87C0703D-6312-43E2-8651-37C10EB00D84Q57168692-CB137E87-15AF-4440-B6FD-33A1BACC3277Q57177786-3F9986B3-AC50-4407-B8B8-E269C4F459D5
P2860
Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimer's disease
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Pre- and post-synaptic cortica ...... stages of Alzheimer's disease
@ast
Pre- and post-synaptic cortica ...... stages of Alzheimer's disease
@en
type
label
Pre- and post-synaptic cortica ...... stages of Alzheimer's disease
@ast
Pre- and post-synaptic cortica ...... stages of Alzheimer's disease
@en
prefLabel
Pre- and post-synaptic cortica ...... stages of Alzheimer's disease
@ast
Pre- and post-synaptic cortica ...... stages of Alzheimer's disease
@en
P2093
P2860
P1476
Pre- and post-synaptic cortica ...... stages of Alzheimer's disease
@en
P2093
Douglas G Walker
Lucia I Sue
Marwan N Sabbagh
Pamela E Potter
Paula K Rauschkolb
Yoga Pandya
P2860
P2888
P356
10.1007/S00401-011-0831-1
P577
2011-05-01T00:00:00Z